Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration

  title={Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration},
  author={Barbara M Davit and P E Nwakama and Gary Buehler and Dale P. Conner and Samer Haidar and Devvrat T. Patel and Yongsheng Yang and Lawrence X. Yu and Janet Woodcock},
  journal={Annals of Pharmacotherapy},
  pages={1583 - 1597}
Background: In the US, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the generic formulation provides the same rate and extent of absorption as (ie, is bioequivalent to) the innovator drug product. Thus, most orally administered generic drug products in the US are approved based on results of one or more clinical bioequivalence studies. Objective: To evaluate how well the bioequivalence measures of generic drugs approved in the US over a 12… 

Figures and Tables from this paper

The belief that generic drugs are inferior to brand name drugs has been always under debate. Especially since the price of generic drugs is generally far cheaper than brand-name drugs. Although, this
Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance
The FDA Office of Generic Drugs’ (OGD’s) Clinical Safety Surveillance Staff (CSSS) has developed investigative processes that complement the broader FDA safety efforts that focus on the potential impact of allowable differences and equivalence determinations for generic drugs.
An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction
It is imperative that complaints about generic drug substitution be investigated thoroughly to determine if the generic drug is actually meeting bioequivalence standards and if there is a rational, mechanistic explanation for the purported reduction in benefits or increase in risks attributed to theGeneric drug.
Pharmacokinetics and Generic Drug Switching: A Regulator’s View
It is described why it is of the opinion that the current regulatory approach to the evaluation of generic drugs based on average bioequivalence is sufficient to expect therapeutic equivalence in the clinical setting.
The Safety of Generic Prescription Drugs in the United States
Concerns about safety of generics are not limited to patients, but extend to other stakeholders including physicians and pharmacists, and the lack of quality control at several product manufacturing sites of prominent manufacturers outside the USA has accentuated concerns about their safety.
Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products?
Concerns regarding the presumed inferiority of generic immunosuppressants should be assuaged by regulatory requirements for bioequivalency testing, transplant society position statements, and pharmacokinetic and clinical studies.
Chapter 2 Fundamentals of Bioequivalence
US regulatory requirements for bioavailability (BA) and bioequivalence (BE) studies in drug applications originated from a report issued by the Congressional Office of Technology Assessment in 1974 and subsequently became the BA/BE regulations in 1977.
Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence
There is no evidence that introduction of generic drugs approved using product-specific therapeutic equivalence determinations was associated with worse clinical outcomes than those among initiators of the brand-name versions of the same products.
Bioequivalence of Generic Drugs Commercialised on the Canadian Market
Data indicates that health care professionals amongst others, lack crucial information to make a responsible decision on the use of generics, and if the generics were bioequivalent to their reference drug.
Assessment of Purity Parameters of Generic and Brand Name Losartan Potassium
This study compared the pharmaceutical quality of four generic losartan potassium formulations with the brand-name product: Cozaar® to show that three of the four generic products had low content of the active ingredient.


Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications
It was observed that most of the consistent and borderline highly variable drugs underwent extensive first pass metabolism and drug product dissolution variability was high for about half of the inconsistentlyhighly variable drugs.
What’s the problem with generic antiepileptic drugs?
Two pharmacokinetic measures, the area under the drug concentration-time curve (AUC) and maximum concentration (Cmax), are used to determine bioequivalence (and by extension from these surrogate measures, therapeutic equivalence), and two reviews have been conducted by the FDA.
Generic drugs and the prescribing physician.
FDA procedures for approving generic drug products are described and the role of the states in generic substitution and the availability of information from the FDA on the therapeutic equivalence of drug products is described.
Drug substitution in transplantation: a National Kidney Foundation White Paper.
Generic antiepileptic drugs
  • S. Shaw, G. Krauss
  • Medicine, Political Science
    Current treatment options in neurology
  • 2008
Although generic AEDs are generally safe and effective for most patients, the current bioequivalence standards may not be sufficient for certain patient populations and for certain drugs, requiring vulnerable patients to be monitored very carefully when converting to generic Aeds.
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
Clinical evidence does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs, and a substantial number of editorials counsel against the interchangeability of generic drugs.
Understanding the scientific issues embedded in the generic drug approval process.
Absorption Rate Vs. Exposure: Which Is More Useful for Bioequivalence Testing?
It was concluded that use of Cmax/AUClqc should be discouraged and that defining bioequivalence in terms of rate and extent of absorption has major problems.
Bioavailability and Bioequivalence: An FDA Regulatory Overview
FDA's recommendations for drug sponsors who intend to establish bioavailability and/or demonstrate bioequivalence for their pharmaceutical products during the developmental process or after approval are provided.